Patient age does not affect mefloquine concentrations in erythrocytes and plasma during the acute phase of falciparum malaria  by Vieira, José Luiz Fernandes et al.
braz j infect dis 2 0 1 6;2  0(5):482–486
www.elsev i er .com/ locate /b j id
The Brazilian Journal of
INFECTIOUS  DISEASES
Original article
Patient  age  does not affect  meﬂoquine
concentrations in erythrocytes  and  plasma  during
the acute  phase  of  falciparum  malaria
José Luiz Fernandes Vieiraa,∗, Larissa Maria Guimarães Borgesa,
Michelle Valéria Dias Ferreiraa, Juan Gonzalo Bardarez Riveraa,
Margarete do Socorro Mendonc¸a  Gomesb
a Universidade Federal do Pará (UFPA), Instituto de Ciências da Saúde, Belám, PA, Brazil
b Laboratório Central de Saúde Pública do Amapá (LACEN-AP), Macapá, AP, Brazil
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 10 May 2016
Accepted 13 July 2016
Available online 16 August 2016
Keywords:
Malaria
Infectious disease
Parasitology
Meﬂoquine
a  b  s  t  r  a  c  t
Objective: To evaluate whether patient age has a signiﬁcant impact on meﬂoquine concen-
trations in the plasma and erythrocytes over the course of treatment for uncomplicated
falciparum malaria.
Methods: A total of 20 children aged between 8 and 11 years and 20 adult males aged
between 22 and 41 years with uncomplicated falciparum malaria were enrolled in the
study. Meﬂoquine was administered to patients in both age groups at a dose of 20 mg kg−1.
The steady-state drug concentrations were measured by reversed-phase high performance
liquid chromatography.
Results: All patients had an undetectable meﬂoquine concentration on day 0. In adults, the
plasma meﬂoquine concentrations ranged from 770 to 2930 ng mL−1 and the erythrocyte
concentrations ranged from 2000 to 6030 ng mL−1. In children, plasma meﬂoquine concen-
trations ranged from 881 to 3300 ng mL−1 and erythrocyte concentrations ranged from 3000
to  4920 ng mL−1. There was no signiﬁcant correlation between meﬂoquine concentrations
in  the plasma and erythrocytes in either adults or children.
Conclusion: In the present study, we observed no effect of patient age on the steady-state
concentrations of meﬂoquine in the plasma and erythrocytes. We  found that the meﬂo-
quine concentration in the erythrocytes was approximately 2.8-times higher than in the
plasma. There were no signiﬁcant correlations between meﬂoquine concentrations in theerythrocytes and plasma for either age group.
© 2016 Sociedade Brasileira de Infectologia. Published by Elsevier Editora Ltda. This is an
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ntroduction
eﬂoquine is a quinoline methanol compound which is effec-
ive against the asexual blood stages of Plasmodium falciparum.
t was ﬁrst introduced in 1984 for clinical use in Thailand. Cur-
ently the drug is used for the treatment of the acute phase
f malaria, either alone or in combination with artesunate,
r as preventative monotherapy for individuals traveling to
ndemic areas.1,2
The exact mechanism of action of meﬂoquine remains
nknown. However, it probably induces morphological
hanges in the early ring stages of P. falciparum to inhibit
aem polymerization. Administration of meﬂoquine results in
ormation of the meﬂoquine-ferriprotoporphyrin IX complex,
hich is toxic to the parasite.3,4 The concentration of meﬂo-
uine within erythrocytes is one of the major determinants
f its therapeutic efﬁcacy. Thus, it is likely that a change in
xposure to meﬂoquine would alter the concentration of the
rug within red blood cells, and consequently, the treatment
utcomes.5,6 Studies investigating the pharmacokinetics of
eﬂoquine have demonstrated that the concentration of the
rug in blood components is inﬂuenced by several factors
ncluding gender, body weight, disease severity, parasitemia
t hospital admission, drug malabsorption, vomiting, drug for-
ulation, and ingestion of certain foods.6,7
It is plausible that the patient’s age may also affect the con-
entration of meﬂoquine in the blood components. A higher
ate of therapeutic failure has been reported in children com-
ared to adults. This was found to be associated with reduced
oncentrations of meﬂoquine in the blood as a result of malab-
orption, diarrhea or vomiting.6,7 As children are at higher risk
or cerebral malaria, the efﬁcacy of antimalarial drugs needs
o be carefully evaluated. However, there is limited data on the
ffect of age on the concentration of meﬂoquine within eryth-
ocytes. Therefore, the aim of this study was to determine
hether the patient’s age has an effect on the concentration of
eﬂoquine in the plasma and erythrocytes during treatment
f the acute phase of uncomplicated falciparum malaria.
aterials  and  methods
thical  statement
he study was approved by the Ethical Committee of
ssociac¸ão Educacional da Amazônia-SEAMA (079/08). All
dult patients and caretakers or guardians of the children
nrolled in the study were informed about the goals of the
tudy, as well as the risks and beneﬁts, before giving writ-
en informed consent prior to entering the study according to
he National Committee of Ethics in Research (CONEP; 196/96).
he children received verbal instructions about the study, and
he collection of blood was performed in the presence of their
aretakers or guardians.
tudy  location  and  patientshe study was carried out at the Reference Center for Tropical
isease in Macapa (Brazil), which is located in an area of low
alarial transmission alongside the Amazon River. A total of6;2 0(5):482–486 483
20 male children and 20 male adults with slide-conﬁrmed P.
falciparum infection were enrolled in the study. The exclusion
criteria were signs or symptoms of severe or mixed malaria
(jaundice, renal impairment, severe anemia, or an altered level
of consciousness), parasitemia above 5%, a known hypersen-
sitivity or allergy to meﬂoquine, individuals that had used
antimalarial drugs in the four weeks prior to admission, or
individuals with a known history of psychiatric disorders.
Clinical  and  laboratory  assessment
All patients underwent clinical and laboratory evaluation at
admission on day 0 (D0) and on days 3, 7, 14, 28 and 42. A com-
plete blood count was performed on D0 and day 3 (D3). Blood
samples for the measurement of meﬂoquine were collected
on D0 and D3.
Meﬂoquine  treatment
Each participant received multiple oral doses of 250 mg meﬂo-
quine base tablets (Farmanguinhos; Brazilian Health Ofﬁce)
on days 1 and 2.1,8 The dose was adjusted for the weight of
the patient to receive a total dose of 20 mg/kg. The drug was
administered with water 30 min  after a typical Amazonian
breakfast. No additional food or drink was provided for 2 h fol-
lowing administration of the drug. In case of vomiting within
2 h of meﬂoquine administration, the patients were carefully
supervised by clinical staff.
Blood  sample  collection  and  measurement  of  meﬂoquine
Venous blood samples (4 mL)  were collected from each patient
in lithium heparin tubes on D0 and 24 h after the last dose
of meﬂoquine (D3). After collection, the samples (4 mL)  were
immediately centrifuged at 500 × g for 10 min  at 4 ◦C for the
separation of plasma. A cell wash buffer was added to the
erythrocyte pellet, which was then centrifuged at 500 × g for
10 min. This procedure was repeated ﬁve times for the separa-
tion of erythrocytes. The samples were stored at −80 ◦C until
analysis.
A reversed-phase high performance liquid chromatogra-
phy (HPLC) system with ultraviolet detection (ProStar; Varian,
Walnut, CA) was used for the analysis of meﬂoquine after
liquid-liquid extraction of the drug from the blood compo-
nents with methyl tert-butyl ether at pH 4.0. The separation
was carried out using a reversed-phase column (ODS C18;
4.6 mm × 250 mm,  5 m internal diameter; Supelco Inc., Belle-
fonte, PA) with a mobile phase composed of acetonitrile:
phosphate buffer (pH 2.5) with a ratio of 42:58. Quinidine
(2.5 g/mL) was used as the internal standard. The within-day
and day-to-day coefﬁcients of variation for the laboratory con-
ditions were 6.7% and 8.1%, respectively. The assay was linear
from 150 to 5000 ng/mL and the detection limit was 50 ng/mL.
The mean recovery was 95%. The stability of blank plasma
spiked with meﬂoquine was 60 days.9Data  analysis
The data are described as the median value and measurement
range. The Mann–Whitney U test was used to compare the
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Table 1 – Baseline characteristics of patients included in the study.
Parameter Children (n = 20) Adults (n = 20)
Age, yearsa 9 (8–11) 31 (22–41)
Weight, kga 23 (19–26) 67 (54–78)
Parasitaemia, microliterb 2100 (900–4500) 2600 (800–5100)
Time for clearance of parasites, hoursa 30.5 (24–48) 29.5 (24–48)
Time for fever clearance, hoursa 20 (12–30) 18 (12–28)
White blood cells count, microlitera 11.300 (7.600–13.000) 9300 (5.200–12700)
Erythrocyte count X106, microlitera 3.21 (3.1–4.1) 4.11 (3.9–4.9)
a Data are presented as median and ranges.
b Data are presented as geometrical mean.
Table 2 – Concentrations of meﬂoquine determined in the plasma and erythrocytes of children and adults with
uncomplicated falciparum malaria.
Age groups n Meﬂoquine in plasmaa (ng mL−1) Meﬂoquine in erythrocytesb (ng mL−1) Ratio erythrocyte to plasmab
Children 20 1530 (881–3300) 4380 (3000–4920) 2.86 (1.37–4.97)
Adult 20 1610 (770–2930) 4220 (2000–6030) 2.72 (0.89–3.89)
 of ch
This study investigated the effect of age on the concentration
of meﬂoquine in the plasma and erythrocytes of patients with
uncomplicated falciparum malaria in the Amazon basin. Drug
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Fig. 1 – Ratio of meﬂoquine concentrations in thea Data are presented as median and ranges.
b Ratio of meﬂoquine concentrations in the erythrocytes and plasma
concentrations of meﬂoquine in the plasma and erythrocytes
for both age groups. The Spearman’s correlation coefﬁcient
was used to estimate the correlation between the meﬂoquine
concentrations in the erythrocytes and plasma for both age
groups. All p-values were two-tailed and p < 0.05 was consid-
ered to be statistically signiﬁcant. All statistical analyses were
performed with Statistica software (version 7.0; StatSoft Inc.,
Tulsa, OK).
Results
The baseline characteristics of all patients are shown in
Table 1. The geometric mean parasite density was similar for
both age groups. All patients completed the 42-day follow-up
period. There was no resurgence of the parasite in the periph-
eral blood, and all patients showed an adequate response to
treatment as demonstrated by complete clearance of parasites
from the peripheral blood within three days of starting treat-
ment. The mean parasite clearance times were 30.5 h (ranged
from 24 to 48 h) and 29.5 h (ranged from 24 to 48 h) h in chil-
dren and adults, respectively. The mean time for the fever to
clear was 20 h (ranged from 12 to 30 h) in the children and
18 h (ranged from 12 to 28 h) in the adults. The drug was
well tolerated, as only two children experienced slight nau-
sea and dizziness and there was no report of vomiting after
drug intake.
All patients had no measurable concentration of meﬂo-
quine on D0. In adults, the concentration of meﬂoquine in
the plasma ranged from 770 to 2930 ng mL−1 and from 2000 to
6030 ng mL−1 in the erythrocytes. The erythrocyte-to-plasma
concentration ratio ranged from 0.89 to 3.89. In children,
the concentration of meﬂoquine in the plasma ranged from
881 to 3300 ng mL−1 and from 3000 to 4920 ng mL−1 in the
erythrocytes. The erythrocyte-to-plasma concentration ratio
ranged from 1.37 to 4.97 in the children. The meﬂoquine
concentrations were similar in the adults and children in
both the plasma (U = 210; p = 0.60) and erythrocyte (U = 228;ildren and adults.
p = 0.94) concentrations. A similar result was found for
the erythrocyte-to-plasma concentration ratio between the
different age groups (U = 192; p = 0.34). The meﬂoquine con-
centrations found in the erythrocytes and plasma for both
age groups are presented in Table 2, and the erythrocyte-to-
plasma concentration ratios are presented in Fig. 1. There
were no signiﬁcant correlations between the concentration of
meﬂoquine in the erythrocytes and plasma of adults (s = 0.102;
p = 0.32) or children (s = 0.215; p = 0.21).
Discussionerythrocytes and plasma of children and adults on D3 after
the commencement of treatment. The box represents the
median value and the ﬁrst and third quartiles, and the
whiskers represent the maximum and minimum values.
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dministration and the occurrence of vomiting and diarrhea
ere carefully monitored by the clinical research staff.
This is the ﬁrst time that plasma meﬂoquine concentra-
ions have been measured in a riverside population from
he Brazilian Amazon basin. The concentration of meﬂoquine
ound in adult patients was similar to that reported in previous
tudies which investigated healthy Caucasian volunteers and
atients with uncomplicated falciparum malaria from Thai-
and and Peru.10–12 In children, the median concentration of
eﬂoquine in the plasma was similar to that obtained in a
tudy including Karen children.13 Furthermore, there were no
igniﬁcant differences in meﬂoquine concentrations between
hildren and adults. This is consistent with previous stud-
es which investigated and compared the pharmacokinetic
arameters of meﬂoquine in patients with uncomplicated fal-
iparum malaria of different age groups. These studies only
ound an effect of body weight on drug clearance in children
ged from 6 to 24 months when compared to older chil-
ren (aged from 5 to 12 years), which were similar to adult
atients.14–17 In addition, the concentrations of meﬂoquine
n all patients were above 500 ng mL−1, which was associated
ith high rates of treatment efﬁcacy.15,18
In the erythrocytes, the meﬂoquine concentrations were
lso similar for both age groups. Furthermore, the median
oncentration of meﬂoquine in the erythrocytes was about
.8-times higher than in the plasma for both age groups. This
s consistent with an in vitro study which reported a rela-
ively constant distribution of meﬂoquine in the erythrocytes
nd plasma, with a ratio of approximately 2:1, suggest-
ng the potential accumulation of meﬂoquine within the
rythrocytes.19 Despite the high binding of meﬂoquine to
lasma proteins, it passively crosses the membrane and binds
o the membrane phospholipids and ferriprotoporphirin IX,
orming a meﬂoquine-ferriprotoporphirin IX complex which
s toxic to the Plasmodium. This complex is responsible for
he high drug concentration observed in parasitized eryth-
ocytes, which is approximately 3- to 4-times higher than
on-parasitized erythrocytes.19–23
On the other hand, the ﬁndings of the study were not con-
istent with a previous study on the distribution of meﬂoquine
n the blood components of patients with uncomplicated
alciparum malaria in Thailand, which reported similar con-
entrations of meﬂoquine in the whole blood and plasma.
urthermore, another study in the same population group
hich investigated the inﬂuence of gender on meﬂoquine con-
entrations in blood components reported drug accumulation
n the plasma, with the plasma-to-erythrocytes ratio ranging
rom 1.59 to 3.75. There are several possible explanations for
he discrepancies between studies, including parasitemia at
dmission, disease severity, meﬂoquine formulation, or the
ime between drug administration and blood sampling.11,24,10
There were no signiﬁcant correlations between the concen-
ration of meﬂoquine in the plasma and erythrocytes for either
ge group. This may be due to the afﬁnity of the drug to other
lood components, rather than the plasma or erythrocytes.
his is in agreement with two studies which evaluated the
istribution of meﬂoquine in the blood components of Thai
atients with acute uncomplicated falciparum malaria and in
ealthy Caucasians. Both studies reported that the meﬂoquine
oncentrations in blood components was highest in white
16;2 0(5):482–486 485
blood cells, followed by platelets, plasma, serum, whole blood,
and lowest in erythrocytes.24,10
A potential limitation of the present study is that only
one blood sample was collected from each patient to esti-
mate meﬂoquine concentrations in both blood components.
However, measuring anti-malarial drugs with a longer half-
life in the steady state appears to provide reliable data which
can be used to estimate the exposure of patients to these
medicines.25
Conclusions
In the present study, we observed no effect of patient age
on the steady-state concentrations of meﬂoquine in plasma
and in erythrocytes. In addition, the concentration of the
drug in erythrocytes was approximately 2.8-times higher
than in plasma. Finally, there were no signiﬁcant correlations
observed between the concentrations of meﬂoquine in the
erythrocytes and the plasma for either age group.
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